Celldex Therapeutics, Inc. (CLDX)
USD 20.66
(-0.24%)
USD 20.66
(-0.24%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -141.42 Million USD | -15.19% |
| 2022 | -122.78 Million USD | -74.13% |
| 2021 | -70.51 Million USD | -17.95% |
| 2020 | -59.78 Million USD | -18.68% |
| 2019 | -50.37 Million USD | 66.68% |
| 2018 | -151.18 Million USD | -62.51% |
| 2017 | -93.03 Million USD | 27.62% |
| 2016 | -128.53 Million USD | -1.05% |
| 2015 | -127.19 Million USD | -7.72% |
| 2014 | -118.08 Million USD | -44.79% |
| 2013 | -81.55 Million USD | -37.93% |
| 2012 | -59.12 Million USD | -31.97% |
| 2011 | -44.79 Million USD | -1668.61% |
| 2010 | -2.53 Million USD | 93.07% |
| 2009 | -36.52 Million USD | 23.11% |
| 2008 | -47.5 Million USD | -119.52% |
| 2007 | -21.63 Million USD | -6.21% |
| 2006 | -20.37 Million USD | -12.58% |
| 2005 | -18.09 Million USD | -37.06% |
| 2004 | -13.2 Million USD | -4.22% |
| 2003 | -12.66 Million USD | 8.39% |
| 2002 | -13.82 Million USD | 39.22% |
| 2001 | -22.75 Million USD | -3.54% |
| 2000 | -21.97 Million USD | -94.31% |
| 1999 | -11.3 Million USD | 78.17% |
| 1998 | -51.8 Million USD | -295.42% |
| 1997 | -13.1 Million USD | -21.3% |
| 1996 | -10.8 Million USD | -30.12% |
| 1995 | -8.3 Million USD | 28.45% |
| 1994 | -11.6 Million USD | -48.72% |
| 1993 | -7.8 Million USD | -116.67% |
| 1992 | -3.6 Million USD | -5.88% |
| 1991 | -3.4 Million USD | -240.0% |
| 1990 | -1 Million USD | 9.09% |
| 1989 | -1.1 Million USD | 8.33% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -35.84 Million USD | -9.25% |
| 2024 Q1 | -32.8 Million USD | 24.24% |
| 2023 Q3 | -38.26 Million USD | -25.43% |
| 2023 Q1 | -22.41 Million USD | 5.39% |
| 2023 Q4 | -43.3 Million USD | -13.19% |
| 2023 Q2 | -30.5 Million USD | -36.08% |
| 2023 FY | -141.42 Million USD | -15.19% |
| 2022 FY | -122.78 Million USD | -74.13% |
| 2022 Q1 | -21.56 Million USD | -7.03% |
| 2022 Q2 | -52.56 Million USD | -143.78% |
| 2022 Q3 | -26.78 Million USD | 49.05% |
| 2022 Q4 | -23.69 Million USD | 11.55% |
| 2021 Q3 | -20.45 Million USD | -52.94% |
| 2021 Q4 | -20.14 Million USD | 1.49% |
| 2021 FY | -70.51 Million USD | -17.95% |
| 2021 Q2 | -13.37 Million USD | 19.14% |
| 2021 Q1 | -16.53 Million USD | 24.48% |
| 2020 FY | -59.78 Million USD | -18.68% |
| 2020 Q2 | -11.03 Million USD | 12.63% |
| 2020 Q3 | -14.22 Million USD | -28.95% |
| 2020 Q4 | -21.9 Million USD | -53.97% |
| 2020 Q1 | -12.62 Million USD | -20.85% |
| 2019 Q3 | -11.41 Million USD | 3.11% |
| 2019 FY | -50.37 Million USD | 66.68% |
| 2019 Q1 | -17.23 Million USD | -83.35% |
| 2019 Q2 | -11.77 Million USD | 31.67% |
| 2019 Q4 | -10.44 Million USD | 8.46% |
| 2018 Q3 | -7.24 Million USD | 55.85% |
| 2018 Q4 | -9.4 Million USD | -29.81% |
| 2018 Q1 | -118.13 Million USD | -2975.55% |
| 2018 Q2 | -16.4 Million USD | 86.11% |
| 2018 FY | -151.18 Million USD | -62.51% |
| 2017 Q2 | -28.56 Million USD | 16.62% |
| 2017 Q4 | -3.84 Million USD | 85.43% |
| 2017 FY | -93.03 Million USD | 27.62% |
| 2017 Q1 | -34.26 Million USD | -6.05% |
| 2017 Q3 | -26.36 Million USD | 7.71% |
| 2016 Q2 | -31.95 Million USD | 7.85% |
| 2016 FY | -128.53 Million USD | -1.05% |
| 2016 Q4 | -32.3 Million USD | -9.15% |
| 2016 Q1 | -34.67 Million USD | -6.09% |
| 2016 Q3 | -29.59 Million USD | 7.37% |
| 2015 FY | -127.19 Million USD | -7.72% |
| 2015 Q1 | -30.17 Million USD | 5.18% |
| 2015 Q4 | -32.68 Million USD | -2.2% |
| 2015 Q2 | -32.35 Million USD | -7.24% |
| 2015 Q3 | -31.98 Million USD | 1.17% |
| 2014 Q2 | -28.27 Million USD | 5.45% |
| 2014 Q4 | -31.82 Million USD | -13.31% |
| 2014 FY | -118.08 Million USD | -44.79% |
| 2014 Q1 | -29.9 Million USD | -35.54% |
| 2014 Q3 | -28.08 Million USD | 0.68% |
| 2013 FY | -81.55 Million USD | -37.93% |
| 2013 Q1 | -17.33 Million USD | -3.12% |
| 2013 Q4 | -22.06 Million USD | 4.66% |
| 2013 Q3 | -23.14 Million USD | -21.69% |
| 2013 Q2 | -19.01 Million USD | -9.72% |
| 2012 Q1 | -13.51 Million USD | -6.16% |
| 2012 Q4 | -16.8 Million USD | -11.85% |
| 2012 FY | -59.12 Million USD | -31.97% |
| 2012 Q3 | -15.02 Million USD | -9.1% |
| 2012 Q2 | -13.77 Million USD | -1.9% |
| 2011 Q3 | -11.77 Million USD | -15.01% |
| 2011 FY | -44.79 Million USD | -1668.61% |
| 2011 Q1 | -10.05 Million USD | -144.39% |
| 2011 Q4 | -12.73 Million USD | -8.15% |
| 2011 Q2 | -10.23 Million USD | -1.76% |
| 2010 Q3 | -9.08 Million USD | 4.6% |
| 2010 Q2 | -9.52 Million USD | -44.71% |
| 2010 Q4 | 22.66 Million USD | 349.38% |
| 2010 Q1 | -6.58 Million USD | 49.15% |
| 2010 FY | -2.53 Million USD | 93.07% |
| 2009 FY | -36.52 Million USD | 23.11% |
| 2009 Q1 | -7.7 Million USD | -3.36% |
| 2009 Q2 | -8.7 Million USD | -13.0% |
| 2009 Q3 | -7.17 Million USD | 17.59% |
| 2009 Q4 | -12.94 Million USD | -80.42% |
| 2008 Q3 | -7.65 Million USD | 25.38% |
| 2008 FY | -47.5 Million USD | -119.52% |
| 2008 Q1 | -22.13 Million USD | -321.24% |
| 2008 Q4 | -7.45 Million USD | 2.65% |
| 2008 Q2 | -10.26 Million USD | 53.64% |
| 2007 Q4 | -5.25 Million USD | -0.01% |
| 2007 Q1 | -5.62 Million USD | 9.43% |
| 2007 Q3 | -5.25 Million USD | 4.57% |
| 2007 FY | -21.63 Million USD | -6.21% |
| 2007 Q2 | -5.5 Million USD | 2.15% |
| 2006 Q4 | -6.21 Million USD | -12.53% |
| 2006 FY | -20.37 Million USD | -12.58% |
| 2006 Q1 | -2.97 Million USD | 25.35% |
| 2006 Q2 | -5.67 Million USD | -90.86% |
| 2006 Q3 | -5.52 Million USD | 2.64% |
| 2005 FY | -18.09 Million USD | -37.06% |
| 2005 Q4 | -3.97 Million USD | 11.85% |
| 2005 Q3 | -4.51 Million USD | 4.64% |
| 2005 Q2 | -4.73 Million USD | 2.76% |
| 2005 Q1 | -4.86 Million USD | -31.64% |
| 2004 FY | -13.2 Million USD | -4.22% |
| 2004 Q2 | -3.89 Million USD | -104.19% |
| 2004 Q4 | -3.69 Million USD | -0.03% |
| 2004 Q3 | -3.69 Million USD | 5.17% |
| 2004 Q1 | -1.9 Million USD | 52.36% |
| 2003 Q1 | -3.36 Million USD | 3.25% |
| 2003 Q2 | -3.18 Million USD | 5.32% |
| 2003 FY | -12.66 Million USD | 8.39% |
| 2003 Q3 | -2.11 Million USD | 33.54% |
| 2003 Q4 | -4 Million USD | -89.46% |
| 2002 Q2 | -5.16 Million USD | -5.1% |
| 2002 Q4 | -3.47 Million USD | -1158.18% |
| 2002 Q1 | -4.91 Million USD | 28.33% |
| 2002 Q3 | -276.2 Thousand USD | 94.65% |
| 2002 FY | -13.82 Million USD | 39.22% |
| 2001 Q2 | -5.66 Million USD | -41.38% |
| 2001 Q3 | -6.22 Million USD | -9.96% |
| 2001 Q4 | -6.85 Million USD | -10.14% |
| 2001 FY | -22.75 Million USD | -3.54% |
| 2001 Q1 | -4 Million USD | 70.33% |
| 2000 FY | -21.97 Million USD | -94.31% |
| 2000 Q2 | -2.72 Million USD | -28.28% |
| 2000 Q1 | -2.12 Million USD | 41.17% |
| 2000 Q3 | -3.63 Million USD | -33.4% |
| 2000 Q4 | -13.49 Million USD | -271.37% |
| 1999 Q3 | -2.6 Million USD | -8.33% |
| 1999 FY | -11.3 Million USD | 78.17% |
| 1999 Q1 | -2.7 Million USD | -17.39% |
| 1999 Q4 | -3.6 Million USD | -38.81% |
| 1999 Q2 | -2.4 Million USD | 11.11% |
| 1998 Q1 | -1.4 Million USD | 6.67% |
| 1998 Q2 | -1.3 Million USD | 7.14% |
| 1998 Q3 | -46.8 Million USD | -3500.0% |
| 1998 FY | -51.8 Million USD | -295.42% |
| 1998 Q4 | -2.3 Million USD | 95.09% |
| 1997 Q3 | -8 Million USD | -370.59% |
| 1997 Q1 | -1.9 Million USD | 20.83% |
| 1997 Q2 | -1.7 Million USD | 10.53% |
| 1997 Q4 | -1.5 Million USD | 81.25% |
| 1997 FY | -13.1 Million USD | -21.3% |
| 1996 Q1 | -1.9 Million USD | -850.0% |
| 1996 FY | -10.8 Million USD | -30.12% |
| 1996 Q4 | -2.4 Million USD | -4.35% |
| 1996 Q3 | -2.3 Million USD | 46.51% |
| 1996 Q2 | -4.3 Million USD | -126.32% |
| 1995 Q1 | -2.4 Million USD | 45.45% |
| 1995 Q2 | -2.6 Million USD | -8.33% |
| 1995 FY | -8.3 Million USD | 28.45% |
| 1995 Q4 | -200 Thousand USD | 93.55% |
| 1995 Q3 | -3.1 Million USD | -19.23% |
| 1994 Q3 | -3 Million USD | -30.43% |
| 1994 Q2 | -2.3 Million USD | -21.05% |
| 1994 Q1 | -1.9 Million USD | 13.64% |
| 1994 FY | -11.6 Million USD | -48.72% |
| 1994 Q4 | -4.4 Million USD | -46.67% |
| 1993 Q2 | -1.5 Million USD | 11.76% |
| 1993 Q4 | -2.2 Million USD | 8.33% |
| 1993 Q1 | -1.7 Million USD | 0.0% |
| 1993 Q3 | -2.4 Million USD | -60.0% |
| 1993 FY | -7.8 Million USD | -116.67% |
| 1992 Q1 | -1.4 Million USD | -250.0% |
| 1992 Q2 | -1.2 Million USD | 14.29% |
| 1992 FY | -3.6 Million USD | -5.88% |
| 1992 Q3 | -1.1 Million USD | 8.33% |
| 1991 Q3 | -1.5 Million USD | -15.38% |
| 1991 FY | -3.4 Million USD | -240.0% |
| 1991 Q2 | -1.3 Million USD | -44.44% |
| 1991 Q1 | -900 Thousand USD | -12.5% |
| 1991 Q4 | -400 Thousand USD | 73.33% |
| 1990 Q1 | 300 Thousand USD | 0.0% |
| 1990 FY | -1 Million USD | 9.09% |
| 1990 Q4 | -800 Thousand USD | -14.29% |
| 1990 Q3 | -700 Thousand USD | 30.0% |
| 1990 Q2 | -1 Million USD | -433.33% |
| 1989 Q4 | - USD | 0.0% |
| 1989 Q1 | - USD | 0.0% |
| 1989 FY | -1.1 Million USD | 8.33% |
| 1989 Q3 | - USD | 0.0% |
| 1989 Q2 | - USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 45.147% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | -25.202% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -15009.936% |
| Autolus Therapeutics plc | -208.38 Million USD | 32.13% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -1490.555% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | -386.545% |
| Shattuck Labs, Inc. | -87.29 Million USD | -62.007% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | -13.46% |
| CervoMed Inc. | -2.17 Million USD | -6411.845% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 42.414% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -217.082% |
| Aptose Biosciences Inc. | -51.2 Million USD | -176.191% |
| Precision BioSciences, Inc. | -61.31 Million USD | -130.645% |
| Dyadic International, Inc. | -6.79 Million USD | -1981.227% |
| TScan Therapeutics, Inc. | -89.21 Million USD | -58.521% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -1242.086% |
| Nektar Therapeutics | -276.05 Million USD | 48.768% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -24755.712% |
| VYNE Therapeutics Inc. | -28.45 Million USD | -397.079% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | -99.773% |
| Leap Therapeutics, Inc. | -81.41 Million USD | -73.716% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 37.212% |
| GRI Bio, Inc. | -13.03 Million USD | -984.828% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -3320.639% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | -13.978% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -1299.317% |
| Psyence Biomedical Ltd. | -51.15 Million USD | -176.45% |
| IGM Biosciences, Inc. | -246.41 Million USD | 42.606% |
| INmune Bio, Inc. | -30 Million USD | -371.304% |
| Opthea Limited | -220.24 Million USD | 35.785% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | -136.959% |
| Omega Therapeutics, Inc. | -97.42 Million USD | -45.163% |
| Verastem, Inc. | -87.36 Million USD | -61.879% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -160.997% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 12.339% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | -21.234% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 371.176% |
| NextCure, Inc. | -62.72 Million USD | -125.482% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | -643.233% |
| Organovo Holdings, Inc. | -14.67 Million USD | -864.004% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -2680.189% |
| Arvinas, Inc. | -367.3 Million USD | 61.495% |
| Ovid Therapeutics Inc. | -52.33 Million USD | -170.217% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | -425.017% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | -316.335% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 6.391% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | -375.791% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 14.064% |
| Senti Biosciences, Inc. | -92.91 Million USD | -52.207% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -1257.583% |
| Apollomics, Inc. | -172.6 Million USD | 18.06% |
| PureTech Health plc | -65.69 Million USD | -115.275% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | -258.239% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | -92.822% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 3.765% |
| Synaptogenix, Inc. | -6.03 Million USD | -2242.12% |
| ChromaDex Corporation | -4.93 Million USD | -2764.095% |
| Beam Therapeutics Inc. | -132.52 Million USD | -6.717% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -1583.239% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | -172.372% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 1.75% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 73.246% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -1714.428% |
| Gritstone bio, Inc. | -138.49 Million USD | -2.122% |
| Mesoblast Limited | -87.95 Million USD | -60.795% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | -831.097% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | -127.177% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 12.117% |
| MediWound Ltd. | -6.71 Million USD | -2005.852% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 21.013% |
| Fortress Biotech, Inc. | -60.63 Million USD | -133.239% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | -83.457% |
| Achilles Therapeutics plc | -69.66 Million USD | -103.013% |
| Seres Therapeutics, Inc. | -113.72 Million USD | -24.362% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | -172.781% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | -369.957% |
| Zai Lab Limited | -334.62 Million USD | 57.734% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -2383.825% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 39.723% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 5736.867% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | -4.074% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -1742.591% |
| FibroGen, Inc. | -284.23 Million USD | 50.242% |
| Celcuity Inc. | -63.77 Million USD | -121.748% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -439.147% |
| ContextLogic Inc. | -317 Million USD | 55.385% |
| GH Research PLC | -35.58 Million USD | -297.418% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | -73.362% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | -527.041% |
| ImmuCell Corporation | -5.77 Million USD | -2349.157% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 387.043% |
| Amarin Corporation plc | -59.11 Million USD | -139.256% |
| TG Therapeutics, Inc. | 12.67 Million USD | 1216.075% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | -712.297% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -119.389% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | -43.691% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | -560.05% |
| Aptorum Group Limited | -2.82 Million USD | -4906.962% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 76.686% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 37.57% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | -483.911% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 31.103% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | -662.581% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | -21.089% |
| Ardelyx, Inc. | -66.06 Million USD | -114.069% |
| Ainos, Inc. | -13.77 Million USD | -927.04% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | -125.637% |
| Prothena Corporation plc | -147.02 Million USD | 3.808% |
| HilleVax, Inc. | -123.56 Million USD | -14.456% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | -24.201% |
| Celularity Inc. | -196.29 Million USD | 27.951% |
| Rallybio Corporation | -74.56 Million USD | -89.675% |
| Cue Biopharma, Inc. | -50.73 Million USD | -178.771% |
| Omeros Corporation | -117.81 Million USD | -20.045% |
| Humacyte, Inc. | -110.77 Million USD | -27.671% |
| Immunocore Holdings plc | -55.28 Million USD | -155.809% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | -686.416% |
| Blueprint Medicines Corporation | -506.98 Million USD | 72.104% |
| IO Biotech, Inc. | -86.08 Million USD | -64.294% |
| MEI Pharma, Inc. | 17.77 Million USD | 895.528% |
| GT Biopharma, Inc. | -7.59 Million USD | -1761.643% |
| Cabaletta Bio, Inc. | -67.67 Million USD | -108.983% |
| Summit Therapeutics Inc. | -614.92 Million USD | 77.001% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | -302.473% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | -0.017% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 14.693% |
| Pulmatrix, Inc. | -14.12 Million USD | -901.551% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | -301.844% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | -39.798% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | -71.143% |
| Acelyrin, Inc. | -381.64 Million USD | 62.942% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 70.609% |
| Cytokinetics, Incorporated | -526.24 Million USD | 73.125% |
| Vor Biopharma Inc. | -117.86 Million USD | -19.994% |
| Evogene Ltd. | -23.87 Million USD | -492.274% |
| Replimune Group, Inc. | -215.79 Million USD | 34.461% |
| Applied Therapeutics, Inc. | -119.76 Million USD | -18.091% |
| PDS Biotechnology Corporation | -42.94 Million USD | -229.347% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -1702.702% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 78.012% |
| AEON Biopharma, Inc. | -52.55 Million USD | -169.102% |
| BioLineRx Ltd. | -60.61 Million USD | -133.327% |
| Galectin Therapeutics Inc. | -41.06 Million USD | -244.394% |
| Atai Life Sciences N.V. | -40.22 Million USD | -251.604% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | -87.271% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | -381.674% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 51.597% |
| Sagimet Biosciences Inc. | -27.87 Million USD | -407.35% |
| MediciNova, Inc. | -8.57 Million USD | -1549.988% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | -14.725% |
| MiMedx Group, Inc. | 67.43 Million USD | 309.714% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -1588.335% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 40.884% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 77.429% |
| Mereo BioPharma Group plc | -29.46 Million USD | -379.974% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 32.447% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -369.085% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 40.056% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2851.685% |
| Allakos Inc. | -185.7 Million USD | 23.84% |
| scPharmaceuticals Inc. | -54.81 Million USD | -158.035% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | -45.301% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 233.248% |
| NLS Pharmaceutics AG | -12.17 Million USD | -1061.918% |
| Precigen, Inc. | -95.9 Million USD | -47.469% |
| XOMA Corporation | -40.83 Million USD | -246.377% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | -38.833% |
| Incyte Corporation | 597.59 Million USD | 123.666% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -1321.719% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -19.336% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | -61.303% |
| Seer, Inc. | -86.27 Million USD | -63.924% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -481.073% |
| CRISPR Therapeutics AG | -153.61 Million USD | 7.93% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 6.807% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | -302.714% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -1647.776% |
| Akari Therapeutics, Plc | -10 Million USD | -1313.159% |
| Novavax, Inc. | -545.06 Million USD | 74.053% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -2021.998% |
| UroGen Pharma Ltd. | -102.24 Million USD | -38.325% |
| Sutro Biopharma, Inc. | -106.79 Million USD | -32.433% |
| Entera Bio Ltd. | -8.88 Million USD | -1491.056% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | -578.642% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | -35.082% |
| Chimerix, Inc. | -82.09 Million USD | -72.275% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | -82.753% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 29.844% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | -139.781% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 134.093% |
| AnaptysBio, Inc. | -163.61 Million USD | 13.562% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | -889.931% |
| Portage Biotech Inc. | -75.33 Million USD | -87.723% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | -46.324% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | -105.088% |
| OKYO Pharma Limited | -16.82 Thousand USD | -840465.429% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | -954.086% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -1592.324% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | -1171.67% |
| AbCellera Biologics Inc. | -146.39 Million USD | 3.394% |
| Genprex, Inc. | -30.86 Million USD | -358.285% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 40.053% |
| NLS Pharmaceutics AG | -12.17 Million USD | -1061.918% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -2570.48% |
| Daré Bioscience, Inc. | -30.16 Million USD | -368.907% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -2439.576% |
| Bicycle Therapeutics plc | -180.66 Million USD | 21.717% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 67.589% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | -79.126% |
| Erasca, Inc. | -125.04 Million USD | -13.105% |
| bluebird bio, Inc. | -211.91 Million USD | 33.261% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | -476.25% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 184.362% |
| DBV Technologies S.A. | -72.72 Million USD | -94.468% |
| Fortress Biotech, Inc. | -60.63 Million USD | -133.239% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 33.357% |
| CorMedix Inc. | -46.33 Million USD | -205.204% |
| Travere Therapeutics, Inc. | -111.39 Million USD | -26.957% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | -314.736% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | -187.925% |
| Spruce Biosciences, Inc. | -47.91 Million USD | -195.142% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 35.629% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 26.496% |
| Onconetix, Inc. | -37.4 Million USD | -278.054% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -1316.273% |
| Prime Medicine, Inc. | -198.13 Million USD | 28.619% |
| Adagene Inc. | -18.94 Million USD | -646.47% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 41.404% |
| GlycoMimetics, Inc. | -36.89 Million USD | -283.282% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | -18.819% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 29.31% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 206.876% |
| SciSparc Ltd. | -5.12 Million USD | -2661.207% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -117508.562% |
| Minerva Neurosciences, Inc. | -30 Million USD | -371.346% |
| Astria Therapeutics, Inc. | -72.89 Million USD | -94.028% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 720.139% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -209969.068% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 46.048% |
| Marker Therapeutics, Inc. | -14.04 Million USD | -906.906% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 67.875% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -1332.337% |
| 2seventy bio, Inc. | -217.57 Million USD | 34.996% |
| ADMA Biologics, Inc. | -28.23 Million USD | -400.829% |
| Clene Inc. | -49.5 Million USD | -185.692% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | -534.565% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | -186.097% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 56.89% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | -334.592% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 722.487% |
| Absci Corporation | -110.56 Million USD | -27.914% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 103.577% |
| Surrozen, Inc. | -43.04 Million USD | -228.584% |
| Caribou Biosciences, Inc. | -102.07 Million USD | -38.561% |
| Janux Therapeutics, Inc. | -58.29 Million USD | -142.617% |
| Cingulate Inc. | -23.53 Million USD | -500.932% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -1946.137% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -1734.198% |
| Jaguar Health, Inc. | -41.3 Million USD | -242.443% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | -56.778% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | -130.769% |
| Kronos Bio, Inc. | -112.67 Million USD | -25.522% |
| Innoviva, Inc. | 179.72 Million USD | 178.693% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | -104.386% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -2015.617% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | -43.878% |
| Soligenix, Inc. | -6.14 Million USD | -2203.13% |
| AlloVir, Inc. | -190.41 Million USD | 25.727% |
| Century Therapeutics, Inc. | -136.67 Million USD | -3.48% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | -40.45% |
| Kura Oncology, Inc. | -152.63 Million USD | 7.339% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 25110.876% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | -96.708% |
| Eterna Therapeutics Inc. | -21.66 Million USD | -552.709% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | -278.76% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -27.922% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -235.189% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -786.055% |
| Entero Therapeutics, Inc. | -15.79 Million USD | -795.405% |
| HCW Biologics Inc. | -24.99 Million USD | -465.846% |
| C4 Therapeutics, Inc. | -132.49 Million USD | -6.745% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 48.781% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 40.549% |
| Lantern Pharma Inc. | -15.96 Million USD | -786.061% |
| Histogen Inc. | -10.62 Million USD | -1231.598% |
| Surrozen, Inc. | -43.04 Million USD | -228.584% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | -250.714% |
| Kodiak Sciences Inc. | -260.49 Million USD | 45.707% |
| MoonLake Immunotherapeutics | -36 Million USD | -292.779% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | -189.067% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | -20.709% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | -348.355% |
| Moderna, Inc. | -4.71 Billion USD | 97.0% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 61.388% |
| Turnstone Biologics Corp. | -55.2 Million USD | -156.212% |
| Immix Biopharma, Inc. | -15.42 Million USD | -816.819% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | -772.588% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | -81.273% |
| Exelixis, Inc. | 207.76 Million USD | 168.072% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | -4.49% |
| Wave Life Sciences Ltd. | -57.51 Million USD | -145.908% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -26335.327% |
| Alkermes plc | 355.75 Million USD | 139.754% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | -119.389% |
| Arcellx, Inc. | -70.69 Million USD | -100.069% |
| ESSA Pharma Inc. | -26.58 Million USD | -432.041% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -3435.769% |
| Avid Bioservices, Inc. | -140.75 Million USD | -0.48% |
| Insmed Incorporated | -749.56 Million USD | 81.132% |
| Cardiff Oncology, Inc. | -41.44 Million USD | -241.278% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | -5.689% |
| Moolec Science SA | -51.78 Million USD | -173.088% |
| RenovoRx, Inc. | -10.23 Million USD | -1282.222% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | -170.052% |
| Geron Corporation | -184.12 Million USD | 23.189% |
| LAVA Therapeutics N.V. | -41.97 Million USD | -236.944% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | -111.104% |
| Royalty Pharma plc | 1.13 Billion USD | 112.463% |
| OmniAb, Inc. | -50.61 Million USD | -179.399% |
| Alector, Inc. | -130.39 Million USD | -8.465% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | -4.026% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 17.616% |
| Humacyte, Inc. | -110.77 Million USD | -27.671% |
| Structure Therapeutics Inc. | -89.62 Million USD | -57.81% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 56.347% |
| 89bio, Inc. | -142.18 Million USD | 0.534% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -1262.908% |
| Aura Biosciences, Inc. | -76.4 Million USD | -85.097% |
| Immunic, Inc. | -93.61 Million USD | -51.08% |
| Veracyte, Inc. | -74.4 Million USD | -90.083% |
| Genelux Corporation | -28.29 Million USD | -399.802% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | -386.596% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -1919.869% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | -650.976% |
| Immunovant, Inc. | -259.33 Million USD | 45.465% |
| Vericel Corporation | -3.18 Million USD | -4344.657% |
| Fortrea Holdings Inc. | -3.4 Million USD | -4059.676% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | -11.674% |
| XBiotech Inc. | -24.55 Million USD | -475.921% |
| Agenus Inc. | -245.76 Million USD | 42.453% |
| Acasti Pharma Inc. | -12.85 Million USD | -1000.358% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | -1030.176% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | -529.753% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | -786.055% |
| Theravance Biopharma, Inc. | -55.19 Million USD | -156.244% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | -107.207% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | -1034.154% |
| Gain Therapeutics, Inc. | -22.26 Million USD | -535.136% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | -379.567% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | -419.234% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 23.419% |
| United Therapeutics Corporation | 984.8 Million USD | 114.361% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -2575.249% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2851.685% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -2680.189% |
| Silo Pharma, Inc. | -3.7 Million USD | -3721.7% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | -981.934% |
| Pharming Group N.V. | -10.54 Million USD | -1240.813% |
| XOMA Corporation | -40.83 Million USD | -246.377% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | -481.073% |
| Bionomics Limited | -15.49 Billion USD | 99.087% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -385.06% |
| Pyxis Oncology, Inc. | -73.79 Million USD | -91.664% |
| uniQure N.V. | -308.47 Million USD | 54.153% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | -85.107% |
| Cassava Sciences, Inc. | -97.21 Million USD | -45.478% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -3655.714% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | -597.004% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | -14.582% |
| Pluri Inc. | -20.88 Million USD | -577.083% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -1624.386% |
| MeiraGTx Holdings plc | -84.02 Million USD | -68.314% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | -516.759% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | -707.882% |
| CalciMedica, Inc. | -34.35 Million USD | -311.645% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 50.07% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 6.699% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -1127481.085% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | -385.06% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | -34.86% |
| Nutriband Inc. | -5.48 Million USD | -2478.321% |
| Protara Therapeutics, Inc. | -40.42 Million USD | -249.899% |
| Compugen Ltd. | -18.75 Million USD | -654.127% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 103.252% |
| ProKidney Corp. | -35.46 Million USD | -298.751% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -2728.299% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -3187.887% |
| Tango Therapeutics, Inc. | -101.74 Million USD | -39.005% |
| Renovaro Biosciences Inc. | -80.65 Million USD | -75.361% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | -207.127% |
| Benitec Biopharma Inc. | -21.75 Million USD | -550.218% |
| GeoVax Labs, Inc. | -25.96 Million USD | -444.654% |
| Biomea Fusion, Inc. | -117.25 Million USD | -20.617% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 7.661% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | -40.255% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 1104.182% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | -535.35% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 58.255% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 26.706% |
| Imunon, Inc. | -19.51 Million USD | -624.72% |
| BioAtla, Inc. | -123.46 Million USD | -14.553% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 56.785% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | -282.768% |
| Zura Bio Limited | -60.36 Million USD | -134.309% |
| aTyr Pharma, Inc. | -50.38 Million USD | -180.674% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 62.147% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 40.51% |
| Galecto, Inc. | -38.34 Million USD | -268.794% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -209969.068% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 150.224% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 20.15% |
| PolyPid Ltd. | -23.86 Million USD | -492.621% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | -798.989% |
| Forte Biosciences, Inc. | -31.47 Million USD | -349.323% |
| Xencor, Inc. | -126.08 Million USD | -12.168% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | -565.031% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -2021.998% |
| Instil Bio, Inc. | -156.08 Million USD | 9.391% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -1588.335% |
| OncoCyte Corporation | -27.78 Million USD | -409.085% |
| Elevation Oncology, Inc. | -45.7 Million USD | -209.446% |
| Purple Biotech Ltd. | -19.88 Million USD | -611.413% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -1914.945% |
| MacroGenics, Inc. | -9.05 Million USD | -1461.371% |
| Verona Pharma plc | -54.36 Million USD | -160.128% |
| Tharimmune, Inc. | -9.31 Million USD | -1417.626% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -68.398% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | -41.546% |
| Aditxt, Inc. | -32.38 Million USD | -336.768% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -7836.532% |
| Savara Inc. | -54.69 Million USD | -158.563% |
| Curis, Inc. | -47.41 Million USD | -198.292% |
| Carmell Therapeutics Corporation | -15.44 Million USD | -815.689% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | -374.355% |
| BeiGene, Ltd. | -881.7 Million USD | 83.96% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -2728.299% |
| Vincerx Pharma, Inc. | -40.15 Million USD | -252.19% |
| Plus Therapeutics, Inc. | -13.31 Million USD | -962.098% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | -134.201% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | -463.664% |
| Adicet Bio, Inc. | -142.65 Million USD | 0.862% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1834.277% |
| Quantum-Si incorporated | -95.96 Million USD | -47.383% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | -870.169% |
| Generation Bio Co. | -126.61 Million USD | -11.703% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | -71.55% |
| Invivyd, Inc. | -198.64 Million USD | 28.802% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 58.643% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -1528.133% |
| Moolec Science SA | -51.78 Million USD | -173.088% |
| Clearside Biomedical, Inc. | -32.48 Million USD | -335.367% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | -159.875% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | -43.159% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 12.049% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 77.006% |
| Evaxion Biotech A/S | -22.12 Million USD | -539.227% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | -75.175% |
| Tyra Biosciences, Inc. | -69.13 Million USD | -104.572% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -254.814% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | -137.684% |
| Clearmind Medicine Inc. | -11.95 Million USD | -1083.008% |
| Aadi Bioscience, Inc. | -65.76 Million USD | -115.052% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 298.052% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -5576247.571% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -64.653% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 7.558% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 34.075% |
| ImmunityBio, Inc. | -583.19 Million USD | 75.749% |
| Korro Bio, Inc. | -81.17 Million USD | -74.234% |
| Kineta, Inc. | -14.09 Million USD | -903.114% |
| BioVie Inc. | -32.12 Million USD | -340.307% |
| Codexis, Inc. | -76.24 Million USD | -85.505% |
| Celularity Inc. | -196.29 Million USD | 27.951% |
| Virax Biolabs Group Limited | -6.73 Million USD | -2000.367% |
| Cibus, Inc. | -267.62 Million USD | 47.154% |
| Annexon, Inc. | -134.23 Million USD | -5.358% |
| Assembly Biosciences, Inc. | -61.22 Million USD | -130.987% |
| Eyenovia, Inc. | -27.26 Million USD | -418.794% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 755.037% |
| NeurAxis, Inc. | -14.62 Million USD | -866.925% |
| Regulus Therapeutics Inc. | -30.03 Million USD | -370.849% |
| Compass Therapeutics, Inc. | -42.49 Million USD | -232.821% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | -565.76% |
| Notable Labs, Ltd. | -11.26 Million USD | -1155.584% |
| IN8bio, Inc. | -30 Million USD | -371.32% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | -629.73% |
| Vera Therapeutics, Inc. | -95.99 Million USD | -47.337% |
| Lumos Pharma, Inc. | -34.03 Million USD | -315.552% |
| Liquidia Corporation | -78.5 Million USD | -80.16% |
| Mustang Bio, Inc. | -51.6 Million USD | -174.077% |
| Quantum-Si incorporated | -95.96 Million USD | -47.383% |
| Arbutus Biopharma Corporation | -72.84 Million USD | -94.14% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | -41.546% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | -160.147% |
| 180 Life Sciences Corp. | -19.93 Million USD | -609.447% |
| Vaxcyte, Inc. | -402.26 Million USD | 64.842% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 22.459% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1834.277% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | -70.491% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 4800.527% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -5576247.571% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | -262.75% |
| PepGen Inc. | -78.62 Million USD | -79.876% |
| Moleculin Biotech, Inc. | -29.76 Million USD | -375.088% |
| Solid Biosciences Inc. | -96.01 Million USD | -47.299% |
| Palisade Bio, Inc. | -12.3 Million USD | -1049.829% |
| Nutriband Inc. | -5.48 Million USD | -2478.321% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -26335.327% |
| Immuneering Corporation | -53.47 Million USD | -164.494% |
| Belite Bio, Inc | -31.63 Million USD | -347.107% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | -190.964% |
| GeoVax Labs, Inc. | -25.96 Million USD | -444.654% |
| Tourmaline Bio, Inc. | -42.12 Million USD | -235.744% |
| Altimmune, Inc. | -88.44 Million USD | -59.903% |
| Peak Bio, Inc. | -1259.26 USD | -11231019.864% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | -439.147% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | -757.925% |
| Neurogene Inc. | -36.31 Million USD | -289.429% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 13.454% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -1563.675% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | -44.099% |
| Sesen Bio, Inc. | -19.88 Million USD | -611.27% |
| argenx SE | -295.05 Million USD | 52.067% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | -70.491% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | -224.714% |
| Immunome, Inc. | -106.8 Million USD | -32.417% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -817799.655% |
| Design Therapeutics, Inc. | -66.86 Million USD | -111.524% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | -273.341% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | -97.571% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 68.149% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | -26.767% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | -4.671% |
| Athira Pharma, Inc. | -117.67 Million USD | -20.189% |
| XOMA Corporation | -40.83 Million USD | -246.377% |
| Merus N.V. | -154.93 Million USD | 8.72% |
| Quince Therapeutics, Inc. | -31.38 Million USD | -350.626% |
| Rezolute, Inc. | -68.45 Million USD | -106.589% |
| Clene Inc. | -49.5 Million USD | -185.692% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -816.973% |
| BeyondSpring Inc. | -21.02 Million USD | -572.639% |
| Synlogic, Inc. | -57.28 Million USD | -146.9% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | -1088.379% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -1206.383% |
| Peak Bio, Inc. | -1259.26 USD | -11231019.864% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | -278.476% |
| Krystal Biotech, Inc. | 10.93 Million USD | 1393.716% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 1.167% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 56.497% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -2961.92% |
| MannKind Corporation | -11.93 Million USD | -1084.696% |
| Ikena Oncology, Inc. | -68.16 Million USD | -107.477% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | -572.991% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | -52.184% |
| Gossamer Bio, Inc. | -179.81 Million USD | 21.348% |
| CohBar, Inc. | -11.96 Million USD | -1082.307% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | -448.43% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | -369.085% |
| Legend Biotech Corporation | -518.25 Million USD | 72.71% |
| Mural Oncology plc | -207.44 Million USD | 31.824% |
| Disc Medicine, Inc. | -76.42 Million USD | -85.046% |
| Champions Oncology, Inc. | -7.27 Million USD | -1843.774% |
| REGENXBIO Inc. | -263.49 Million USD | 46.326% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | -1232.592% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -197.714% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | -272.343% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | -41.199% |
| Vaxart, Inc. | -82.46 Million USD | -71.502% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 42474.08% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | -276.717% |
| Cellectis S.A. | -101.05 Million USD | -39.947% |
| Longeveron Inc. | -21.41 Million USD | -560.482% |
| Repare Therapeutics Inc. | -93.79 Million USD | -50.784% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 73.613% |
| Inozyme Pharma, Inc. | -71.16 Million USD | -98.723% |
| Revolution Medicines, Inc. | -436.36 Million USD | 67.589% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -2052.321% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | -358.828% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | -103.985% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | -118.484% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -1341.535% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 103.907% |
| Denali Therapeutics Inc. | -145.22 Million USD | 2.613% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -117508.562% |
| Veru Inc. | -93.15 Million USD | -51.825% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | -423.249% |
| Cingulate Inc. | -23.53 Million USD | -500.932% |
| Passage Bio, Inc. | -102.06 Million USD | -38.572% |
| Context Therapeutics Inc. | -23.96 Million USD | -490.168% |
| Exicure, Inc. | -16.91 Million USD | -736.165% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 25.137% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | -274.507% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -2073.382% |
| Nuvalent, Inc. | -126.21 Million USD | -12.05% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -1244.937% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | -62.788% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | -363.034% |
| OmniAb, Inc. | -50.61 Million USD | -179.399% |
| Anew Medical, Inc. | 1.34 Million USD | 10606.379% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | -781.452% |
| Lipocine Inc. | -16.35 Million USD | -764.899% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | -113.015% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | -122.111% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | -235.189% |
| G1 Therapeutics, Inc. | -47.96 Million USD | -194.846% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | -613.171% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 73.881% |
| Ocugen, Inc. | -63.07 Million USD | -124.213% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | -47.734% |
| Q32 Bio Inc. | -112.96 Million USD | -25.202% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | -722.644% |
| Alumis Inc. Common Stock | -154.99 Million USD | 8.751% |
| Equillium, Inc. | -13.33 Million USD | -960.585% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | -134.286% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -1670.555% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | -650.238% |
| Dominari Holdings Inc. | -22.88 Million USD | -518.08% |
| Edesa Biotech, Inc. | -8.37 Million USD | -1588.822% |
| vTv Therapeutics Inc. | -20.25 Million USD | -598.415% |
| Bio-Techne Corporation | 168.1 Million USD | 184.131% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 59.831% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 209.76% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | -16.085% |
| Candel Therapeutics, Inc. | -37.93 Million USD | -272.78% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | -25.556% |
| Nkarta, Inc. | -117.5 Million USD | -20.364% |
| BioCardia, Inc. | -11.57 Million USD | -1122.271% |
| Iterum Therapeutics plc | -38.37 Million USD | -268.583% |